Valuation
- Market cap
- 7,101,000
- Revenue TTM
- $0
- Net income TTM
- $-29,560,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 13,500
- Avg volume
- 78,017
- Day's range
- $1.04 – $1.22
- Shares out
- 6,828,000
- Stochastic %K
- 2%
- Beta
- 0.76
- Analysts
- Strong Sell
- Price target
- $50.00
Company profile
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidne...
Show more
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 858 952 5500
- Website
- https://calcimedica.com
- Address
- 505 Coast Boulevard South, Suite 307, La Jolla, United States
Latest news
No headlines yet.
